Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Sous-étude 06E : Étude générale sur les thérapies combinées dans le cancer de l'œsophage (MK-3475-06E/KEYMAKER-U06)

23 octobre 2026 mis à jour par: Merck Sharp & Dohme LLC

Une étude de phase 1/2 ouverte sur la conception d'une plate-forme parapluie portant sur des agents expérimentaux en association avec le pembrolizumab (MK-3475) avec ou sans chimiothérapie chez des participants atteints d'un cancer de l'œsophage non résécable/métastatique localement avancé de 1 L : sous-étude KEYMAKER-U06 06E

Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts.

Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing.

Researchers want to learn about giving pembrolizumab and investigational agents, with or without chemotherapy to treat ESCC. Ifinatamab deruxtecan (I-DXd), is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells.

The main goal of this study is to learn about the safety of investigational agents and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

The master protocol is MK-3475-U06.

Type d'étude

Interventionnel

Inscription (Estimé)

298

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

  • Allemagne
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Allemagne, 69120
        • Recrutement
        • NCT-Department of Medical Oncology ( Site 1809)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +49 62215637784
    • Free and Hanseatic City of Hamburg
      • Erdgeschoss, Free and Hanseatic City of Hamburg, Allemagne, 22297
        • Recrutement
        • HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 1807)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +4940360352246
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Allemagne, 40225
        • Recrutement
        • Universitaetsklinikum Duesseldorf ( Site 1808)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +492118108751
    • Saxony
      • Dresden, Saxony, Allemagne, 01307
        • Recrutement
        • Universitätsklinikum Carl Gustav Carus - Medical Oncology ( Site 1806)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +493514583016
  • Brésil
      • São Paulo, Brésil, 01246-000
        • Recrutement
        • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1302)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 551138932000
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brésil, 59062-000
        • Recrutement
        • Liga Norte Riograndense Contra o Cancer ( Site 1301)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +55 84 4009-5595
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brésil, 91010-004
        • Recrutement
        • Hospital Nossa Senhora da Conceicao ( Site 1300)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +555133572092
    • São Paulo
      • São Paulo, São Paulo, Brésil, 03102-002
        • Recrutement
        • IBCC - Instituto Brasileiro de Controle do Cancer ( Site 1303)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 551144500300
  • Chili
      • Antofagasta, Chili, 1263521
        • Recrutement
        • Bradford Hill Norte ( Site 1405)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +56442023631
    • Los Lagos Region
      • Port Montt, Los Lagos Region, Chili, 5500243
        • Recrutement
        • Clínica Puerto Montt ( Site 1406)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +56652484800
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chili, 7620002
        • Recrutement
        • Clínica UC San Carlos de Apoquindo ( Site 1403)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +56223748924
      • Santiago, Region M. de Santiago, Chili, 8420383
        • Recrutement
        • Bradfordhill ( Site 1401)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +56220490970
      • Santiago, Region M. de Santiago, Chili, 7560913
        • Recrutement
        • Centro de Oncología de Precisión ( Site 1402)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +56972151681
      • Santiago, Region M. de Santiago, Chili, 7500921
        • Recrutement
        • Fundación Arturo López Pérez ( Site 1400)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +56224205098
  • Chine
    • Anhui
      • Hefei, Anhui, Chine, 230601
        • Recrutement
        • The Second Affiliated Hospital of Anhui Medical University ( Site 9511)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 0551-63839536
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 130021
        • Recrutement
        • Beijing Cancer Hospital ( Site 9500)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: (010)88196317
    • Fujian
      • Xiamen, Fujian, Chine, 361003
        • Recrutement
        • The First Affiliated Hospital of Xiamen University ( Site 9503)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 0592-2139767
    • Henan
      • Zhengzhou, Henan, Chine, 450008
        • Recrutement
        • Henan Cancer Hospital ( Site 9509)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 0371-65587625
    • Jiangsu
      • Xuzhou, Jiangsu, Chine, 221000
        • Recrutement
        • Xuzhou Central Hospital ( Site 9512)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 86051680812397
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 330006
        • Recrutement
        • The First Affiliated Hospital of Nanchang University ( Site 9505)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 86079188692201
  • Corée du Sud
      • Seoul, Corée du Sud, 05505
        • Recrutement
        • Asan Medical Center ( Site 9901)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82230107179
      • Seoul, Corée du Sud, 06351
        • Recrutement
        • Samsung Medical Center ( Site 9900)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82234106518
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, Corée du Sud, 10408
        • Recrutement
        • National Cancer Center ( Site 9902)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82319201694
  • France
      • Paris, France, 75013
        • Recrutement
        • Pitie Salpetriere University Hospital ( Site 9102)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +331 42 16 10 41
    • Finistere
      • Brest, Finistere, France, 29609
        • Recrutement
        • C.H.R.U. de Brest - Hopital Cavale Blanche ( Site 9104)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 33298223428
    • Nord
      • Lille, Nord, France, 59037
        • Recrutement
        • CHU Lille - Institut Coeur Poumon ( Site 9100)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +33320445461
  • Italie
    • Lombardy
      • Milan, Lombardy, Italie, 20132
        • Recrutement
        • Ospedale San Raffaele-Oncologia Medica ( Site 9201)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +390226437615
    • Veneto
      • Padova, Veneto, Italie, 35128
        • Recrutement
        • Istituto Oncologico Veneto IRCCS ( Site 9202)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 390498215910
  • Japon
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 464-8681
        • Recrutement
        • Aichi Cancer Center ( Site 9702)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +81-52-762-6111
    • Chiba
      • Kashiwa, Chiba, Japon, 277-8577
        • Recrutement
        • National Cancer Center Hospital East ( Site 9701)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +81-4-7133-1111
    • Tokyo
      • Chūō, Tokyo, Japon, 104-0045
        • Recrutement
        • National Cancer Center Hospital ( Site 9700)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +81-3-3542-2511
  • Norvège
      • Oslo, Norvège, 0379
        • Recrutement
        • Oslo Universitetssykehus Radiumhospitalet ( Site 1501)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +4723026600
  • Singapour
    • Central Singapore
      • Singapore, Central Singapore, Singapour, 119074
        • Recrutement
        • National University Hospital ( Site 9800)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +65 6908 2222
  • Suisse
      • Geneva, Suisse, 1211
        • Recrutement
        • Hopitaux Universitaires de Geneve HUG. ( Site 1701)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +41 (0)22 372 95 77
    • Kanton Graubünden
      • Chur, Kanton Graubünden, Suisse, 7000
        • Recrutement
        • Kantonsspital Graubuenden ( Site 1700)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +41 81 256 61 11
  • Taïwan
      • Kaohsiung City, Taïwan, 83301
        • Recrutement
        • Kaohsiung Chang Gung Memorial Hospital ( Site 1003)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +88677317123x3679
      • Taichung, Taïwan, 40707
        • Recrutement
        • China Medical University Hospital ( Site 1007)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 886-4-22052121
      • Tainan, Taïwan, 704302
        • Recrutement
        • National Cheng Kung University Hospital ( Site 1001)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +88662353535x4559
      • Taipei, Taïwan, 100225
        • Recrutement
        • National Taiwan University Hospital ( Site 1000)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +886223123456x67680
      • Taipei, Taïwan, 11217
        • Recrutement
        • Taipei Veterans General Hospital ( Site 1005)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +886228712121
      • Taipei, Taïwan, 106
        • Recrutement
        • National Taiwan University Cancer Center ( Site 1010)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 886223220322
      • Taoyuan, Taïwan, 33305
        • Recrutement
        • Chang Gung Memorial Hospital - Linkou Branch ( Site 1006)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +88633281200 #8825
    • Kaohsiung
      • Kaoshiung, Kaohsiung, Taïwan, 807
        • Recrutement
        • Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 1009)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +8867-3121101#7451
  • Tchéquie
    • Brno-mesto
      • Brno, Brno-mesto, Tchéquie, 656 53
        • Recrutement
        • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 9000)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +420543136812
  • Thaïlande
    • Bangkok
      • Ratchathewi, Bangkok, Thaïlande, 10400
        • Recrutement
        • Ramathibodi Hospital ( Site 1103)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +6622004029
    • Changwat Songkhla
      • Hat Yai, Changwat Songkhla, Thaïlande, 90110
        • Recrutement
        • Songklanagarind hospital ( Site 1101)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +6674451469
  • Turquie (Türkiye)
      • Adana, Turquie (Türkiye), 01140
        • Recrutement
        • Adana Medical Park Seyhan Hastanesi ( Site 9404)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +90444 44 84
      • Ankara, Turquie (Türkiye), 06520
        • Recrutement
        • Memorial Ankara Hastanesi ( Site 9406)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +905456177189
      • Ankara, Turquie (Türkiye), 06230
        • Recrutement
        • Hacettepe Universite Hastaneleri ( Site 9401)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +905333319240
      • Ankara, Turquie (Türkiye), 06800
        • Recrutement
        • Ankara Bilkent Şehir Hastanesi ( Site 9403)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +90 312 552 60 00
      • Erzurum, Turquie (Türkiye), 25070
        • Recrutement
        • Atatürk Üniversitesi ( Site 9405)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +905543701653
  • États-Unis
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15232
        • Recrutement
        • UPMC Hillman Cancer Center ( Site 1904)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 412-623-8974

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

  • Has histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic squamous cell carcinoma of the esophagus in first-line (1L) setting.
  • Has measurable disease per RECIST 1.1 as assessed by the local site. investigator or designee/radiology assessment and verified by BICR. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
  • Has had AEs due to previous anticancer therapies that have recovered to ≤Grade 1 or baseline. Endocrine-related AEs that are adequately treated with hormone replacement are elegible.
  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • Has adequate organ function.

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

  • Has had systemic anticancer therapy for locally advanced unresectable or metastatic esophageal cancer.
  • Has tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of fistula.
  • Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention.
  • Has clinically significant corneal disease, history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
  • Has received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor.
  • Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention.
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids.
  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
  • Has inadequate cardiac function assessed as by a corrected QT interval by Fredericia (QTcF) value ≥470 msec.
  • Has clinically significant cardiovascular disease within 6 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
  • Has peripheral neuropathy ≥ Grade 2.
  • Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Has active autoimmune disease that has required systemic treatment in the past 2 years.
  • Has had a history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), has a current diagnosis of ILD, or has clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out.
  • Has active infection requiring systemic therapy.
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Pembrolizumab + Chemotherapy

Participants will receive 400 mg of pembrolizumab via intravenous (IV) infusion every six weeks (Q6W) on Day 1 of each 42-day cycle up to 18 cycles (up to approximately 2 years), and mFOLFOX6 chemotherapy: oxaliplatin 85 mg/m^2 via IV infusion every 2 weeks (Q2W), until progressive disease (PD) or toxicity; leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 via IV infusion Q2W, until PD or toxicity; 5-fluorouracil (5-FU) 400 mg/m^2 bolus IV infusion followed by 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, until PD or toxicity.
Médicament: Leucovorin

IV infusion

Biologique: Pembrolizumab

IV infusion

Autres noms:
  • MK-3475
  • KEYTRUDA®
Médicament: Oxaliplatin

IV infusion

Médicament: Levoleucovorin

IV infusion

Médicament: 5-Fluorouracil (5-FU)

IV Infusion
Expérimental: Pembrolizumab + I-DXd

Participants will receive 200 mg of pembrolizumab via IV infusion Q3W on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years). Participants will also receive up to 12 mg/kg I-XDd Q3W via IV infusion, until PD or toxicity.
Biologique: Pembrolizumab

IV infusion

Autres noms:
  • MK-3475
  • KEYTRUDA®
Biologique: I-DXd

IV infusion

Autres noms:
  • DS-7300a
  • MK-2400
  • Ifinatamab déruxtécan
Médicament: Rescue Medication

Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label
Expérimental: Pembrolizumab + I-DXd + 5-FU IV + Leucovorin or Levoleucovorin

Participants will receive 200 mg pembrolizumab via IV infusion Q3W on Day 1 of each 21-day cycle up to 35 cycles (up to approximately 2 years). Participants will also receive I-DXd up to 12 mg/kg via IV infusion Q3W, until PD or toxicity; 5-FU 400 mg/m^2 bolus IV infusion followed by 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, OR 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, until PD or toxicity; and leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 via IV infusion Q2W, until PD or toxicity.
Médicament: Leucovorin

IV infusion

Biologique: Pembrolizumab

IV infusion

Autres noms:
  • MK-3475
  • KEYTRUDA®
Médicament: Levoleucovorin

IV infusion

Médicament: 5-Fluorouracil (5-FU)

IV Infusion

Biologique: I-DXd

IV infusion

Autres noms:
  • DS-7300a
  • MK-2400
  • Ifinatamab déruxtécan
Médicament: Rescue Medication

Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label
Expérimental: Pembrolizumab + I-DXd + 5-FU IV + Leucovorin or Levoleucovorin + Oxaliplatin

Participants will receive 200 mg of pembrolizumab via IV infusion Q3W on Day 1 of each 21-day cycle up to 35 cycles (up to approximately 2 years). Participants will also receive up to 12 mg/kg I-DXd via IV infusion q3w, until PD or toxicity; 5-FU 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, until PD or toxicity; 60mg/m^2 oxaliplatin via IV infusion Q2W, until PD or toxicity; and leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 via IV infusion Q2W, until PD or toxicity.
Médicament: Leucovorin

IV infusion

Biologique: Pembrolizumab

IV infusion

Autres noms:
  • MK-3475
  • KEYTRUDA®
Médicament: Oxaliplatin

IV infusion

Médicament: Levoleucovorin

IV infusion

Médicament: 5-Fluorouracil (5-FU)

IV Infusion

Biologique: I-DXd

IV infusion

Autres noms:
  • DS-7300a
  • MK-2400
  • Ifinatamab déruxtécan
Médicament: Rescue Medication

Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label
Expérimental: Pembrolizumab + Sacituzumab tirumotecan + 5-FU IV + Leucovorin or Levoleucovorin

Participants will receive 400 mg pembrolizumab via IV infusion Q6W on Day 1 of each 42-day cycle up to 18 cycles (up to approximately 2 years). Participants will also receive sacituzumab tirumotecan 4 mg/kg via IV infusion Days 1, 15, and 29 every 42-day cycle, until PD or toxicity; 5-FU 400 mg/m^2 bolus IV infusion followed by 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, OR 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, until PD or toxicity; and leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 via IV infusion Q2W, until PD or toxicity.
Médicament: Leucovorin

IV infusion

Biologique: Pembrolizumab

IV infusion

Autres noms:
  • MK-3475
  • KEYTRUDA®
Médicament: Levoleucovorin

IV infusion

Médicament: 5-Fluorouracil (5-FU)

IV Infusion

Médicament: Rescue Medication

Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label

Biologique: Sacituzumab tirumotecan

IV infusion

Autres noms:
  • SKB264
  • MK-2870

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants who Experience Dose Limiting Toxicities (DLTs) During the Safety Lead-In Phase
Délai: Up to approximately 28 days

Percentage of participants experiencing toxicities that are possibly, probably, or definitely related to study intervention; that meet pre-defined severity criteria; and result in a change in the given dose.
Up to approximately 28 days
Percentage of Participants who Experience an Adverse Event (AE)
Délai: Up to approximately 77 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience an AE will be reported.
Up to approximately 77 months
Objective Response Rate (ORR)
Délai: Up to approximately 77 months

ORR is defined as a confirmed complete response (CR: the disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). The percentage of participants who experience CR or PR as assessed by BICR will be presented.
Up to approximately 77 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Duration of Response (DOR)
Délai: Up to approximately 77 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.
Up to approximately 77 months
Progression-Free Survival (PFS)
Délai: Up to approximately 77 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.
Up to approximately 77 months
Overall Survival (OS)
Délai: Up to approximately 77 months

OS is defined as the time from allocation/randomization to death due to any cause.
Up to approximately 77 months
Disease Control Rate (DCR)
Délai: Up to approximately 77 months

DCR is defined as a confirmed complete response (CR) or partial response (PR), or stable disease (SD) with at least 6 months PFS per RECIST 1.1 as assessed by BICR.
Up to approximately 77 months
Maximum Plasma Concentration (Cmax) of I-DXd
Délai: At designated time points up to approximately 65 months

Cmax is defined as the peak level I-DXd reaches in the blood plasma. Blood samples collected predose and at multiple timepoints postdose will be used to determine the Cmax of I-DXd when co-administered with other investigational agents.
At designated time points up to approximately 65 months
Time to Maximum Plasma Concentration (Tmax) of I-DXd
Délai: At designated time points up to approximately 65 months

Tmax is defined as the time it took I-DXd to reach its peak level in blood plasma. Blood samples collected predose and at designated timepoints postdose will be used to determine the Tmax of I-DXd when co-administered with other investigational agents.
At designated time points up to approximately 65 months
Area Under the Concentration-Time Curve from Time 0 to Last Measurable Plasma Concentration (AUClast) of I-DXd
Délai: At designated time points up to approximately 65 months

AUClast is defined as the area under the concentration-time curve from time 0 to the last measurable concentration of I-DXd in the blood plasma. Blood samples collected at predose and at designated timepoints postdose will be used to determine the AUClast of I-DXd in combination with other agents.
At designated time points up to approximately 65 months
Area Under the Concentration-Time Curve from Time 0 to the End of the Dosing Period (AUCtau) of I-DXd
Délai: At designated time points up to approximately 65 months

AUCtau is defined as the area under the concentration-time curve from time zero to the end of the dosing period. Blood samples collected at predose and at designated timepoints postdose will be used to determine the AUCtau of I-DXd in combination with other agents.
At designated time points up to approximately 65 months
The Percentage of Participants with Antidrug Antibodies (ADA) Against I-DXd
Délai: Up to approximately 65 months

Blood samples collected at designated timepoints will be used to determine the ADA response to I-DXd. The percentage of participants with ADA will be reported.
Up to approximately 65 months
The Percentage of Participants with Treatment-Emergent ADA Against I-DXd
Délai: Up to approximately 65 months

Blood samples collected at designated timepoints will be used to determine the treatment-emergent ADA response to I-DXd. The percentage of participants who have treatment-emergent I-DXd ADA will be reported.
Up to approximately 65 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Merck Sharp & Dohme LLC

Collaborateurs

Daiichi Sankyo

Les enquêteurs

  • Directeur d'études: Medical Director, Merck Sharp & Dohme LLC

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 juillet 2025

Achèvement primaire (Estimé)

4 janvier 2032

Achèvement de l'étude (Estimé)

4 janvier 2032

Dates d'inscription aux études

Première soumission

13 janvier 2025

Première soumission répondant aux critères de contrôle qualité

13 janvier 2025

Première publication (Réel)

17 janvier 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

27 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 3475-06E
  • MK-3475-06E (Autre identifiant: MSD)
  • U1111-1307-6484 (Identificateur de registre: UTN)
  • jRCT2041240166 (Identificateur de registre: Japan Registry of Clinical Trials (jRCT))
  • 2024-514273-22-00 (Identificateur de registre: EU CT)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner